Amgen

Amgen opens new technology & innovation site in Hyderabad, to invest $200 million

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.

Amgen is said to agree to buy horizon at $26 billion valuation

The US biotechnology giant offered around $116.5 for each Horizon share, said the person, who asked not to be identified as the information is private. The offer price is at a around 20% premium to Horizon’s closing price of $97.29 on Friday.

Syngene: Multi-year contract with Zoetis adds to long-term visibility

The risk to watch is the execution in the field biologics and the pending regulatory approvals

Comment | Cipla takes a calculated risk with generic Sensipar launch

Cipla’s launch of a blockbuster drug made by Amgen even while litigation is ongoing is a risky affair. Here’s why Cipla may have taken a calculated risk

DRL inks pact with Amgen to market three drugs in India

Under the terms of collaboration, DRL will commercialise Xgeva (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India, a company statement said.

Syngene sets up R&D centre for Amgen in Bengaluru

The centre, named Syngene Amgen Research and Development Center (SARC), will be Syngene's fourth such exclusive R&D unit, the company said in a filing to BSE.

Biosimilar insulin Glargine to make $100 m from FY18: Biocon

Biocon R&D team is working on the second phase of the development of oral insulin, and Kiran Mazumdar-Shaw, Chairman & MD, Biocon, hopes that it becomes an approved product in the next 2-3 years.

Dr Reddy's at new high on pact with Amgen, CLSA retains buy

Brokerage CLSA has reiterated its buy rating on the stock with a target price of Rs 4,875 apiece as it believes that differentiated US products can drive company's profit to USD 1 billion by FY20.